Menstrual Cycle Maintenance and Quality of Life: A Prospective Study
Very little is known about the incidence, onset, time course, and symptomatology of premature menopause induced by breast cancer therapy. No prospective study exists. The purpose of the present study is to identify determinants of treatment-related amenorrhea nad its effect on quality of life in a cohort of youg breast cancer patients.
Arms and Interventions
Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
Primary Outcome Measures
- The overall goal of the proposed research is to recruit and follow young breast cancer patients aged 45 and younger, in order to examine menstrual cycle maintenance. [Conclusion of the study]
Secondary Outcome Measures
- Examine possible predictors of treatment-related amenorrhea including age, smoking history, race, and treatment variables [Conclusion of study]
Non-institutional (community dwelling) woman of any race
Between 18-45 years at the first screening visit
Have regular menstrual cycles
Diagnosed with invasive breast cancer stage I, II, III within the previous eight months
Have physician agreement for patient participation
No menstrual bleeding cycles
Psychiatric or psychologic abnormality precluding the informed consent process or which would decrease compliance
Previous malignancy (excepting basal and squamous skin cancer and stage 0 cervical cancer)
Stage IV breast malignancy
Residency outside United States
Contacts and Locations
|1||Memorial Sloan Kettering Cancer Center||New York||New York||United States||10065|
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
- Principal Investigator: Kimberly Van Zee, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)None provided.